Ozempic’s Success Is Bad News for Rivals

The people, companies and trends shaping the global economy.Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.During an all-hands meeting at Apple in January, an employee asked about a spate of executive moves. The company’s chief operating officer recently ret ...  Show more

Stocks and bonds rebounded after President Donald Trump said the US and Iran had “very good” conversations about an end to the conflict in the Middle East. President rump said strikes against Iranian energy infrastructure and power plants would be postponed for five days followin ...  Show more

Bloomberg BNA's Eleanor Tyler joins Tom Keene and Mike McKee to discuss pharmaceutical mergeres, tax inversions, drug pricing, and the renewed efforts by the Federal Trade Commission to regulate an increasingly complicated industry. Learn more about your ad-choices at https://www ...  Show more

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ...  Show more

As a number of existing therapies are being re-purposed to help patients with the most severe Covid-19 symptoms, we speak to a UK-based bioscience company about a drug they've developed and explore how it is being used in Italy. 

Guests: </stro ...

In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry.

How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 1 ...